FDA OKs stem cell trial

California-based biotech company Geron Corp. announced today (Jan. 23) that it has received clearance from the U.S. Food and Drug Administration to begin trials for the world's first clinical study on human embryonic stem cell-based therapy. linkurl:Geron;http://www.geron.com/ plans to initiate a Phase I multicenter clinical trial in up to 10 patients paralyzed due to spinal cord injury. Its treatment -- currently referred to as "GRNOPC1" -- uses embryonic stem cells coaxed to become nerve cells, which are injected into the spinal cord. The FDA had been linkurl:mulling over;http://www.the-scientist.com/blog/display/54544/ the decision ever since Geron filed its 21,000-page application for the trial in March. linkurl:Last May,;http://www.the-scientist.com/blog/display/54647/ the FDA placed a hold on the petition to give them time to review the study. Approval came in a phone call on Wednesday afternoon, said Thomas Okarma, Geron's president and CEO, according to the__ linkurl:Wall Street Journal.;http://online.wsj.com/article/SB123268485825709415.html __"This marks the beginning of what is potentially a new chapter in medical therapeutics -- one that reaches beyond pills to a new level of healing," Okarma said in a statement. "It's an exciting sign that the FDA is satisfied with the initial safety [reviews] of stem cell therapy," Stephen Dunn, director of research at Boca Raton, Fla., securities firm Dawson James, told __The Scientist__. The decision comes hot on the heels of the inauguration of President Barack Obama, who is widely expected to lift former President George Bush's limits on stem-cell research funding. But both the FDA and Geron said the timing of the announcement was coincidental. "The FDA looks to the science on these types of issues, and we approve [such applications] based on a showing of safety," Karen Riley, an FDA spokesperson, told the __Wall Street Journal__. "Political considerations have no role in this process." Geron's linkurl:stock;http://finance.yahoo.com/echarts?s=GERN#chart4:symbol=gern;range=5d;indicator=volume;charttype=line;crosshair=on;ohlcvalues=0;logscale=on;source=undefined soared today following the company's announcement.
**__Related stories:__***linkurl:Stem cell trial nearly a go?;http://www.the-scientist.com/article/blog/55096/
[17th October 2008]*linkurl:First embryonic stem cell trial stalled;http://www.the-scientist.com/blog/display/54647/
[15th May 2008]*linkurl:FDA mulls embryonic stem cell therapy;http://www.the-scientist.com/blog/display/54544/
[11th April 2008]

FDA OKs stem cell trial

The Scientist ARCHIVES

Become a Member of

Meet the Author

Elie Dolgin

Related Research Resources

Study Confirms Safety of Genetically Modified T Cells

Research Resources

Podcasts

Webinars

Videos

Infographics

eBooks

TaqMan Probe & Assays: Unveil What's Possible Together

Meet Aunty and Tackle Protein Stability Questions in Research and Development

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Making Real-Time PCR More Straightforward

Products

Product News

Fujirebio Receives Marketing Clearance for Lumipulse® G pTau 217/ β-Amyloid 1-42 Plasma Ratio In-Vitro Diagnostic Test

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours